NCT02831270

Brief Summary

Serum-creatinine level (s-Cr) is an important factor for predicting perioperative patient's outcome regarding acute kidney injury. Although cardiopulmonary bypass (CPB), an essential procedure for cardiac surgery, dilutes patient's blood components, possible impact of applying acute normovolemic hemodilution (ANH) and CPB on s-Cr has not been well investigated. In patients undergoing cardiac surgery employing moderate hypothermic CPB (age 20-71 years, n=32), ANH will be randomly applied to 15 patients (Group-ANH) but not in 17 patients (Group-C) before initiating CPB. For ANH procedure consisting of 5 ml/kg of blood salvage and administering 5 ml/kg of balanced hydroxyethyl starch (HES) 130/0.4 for 15 min will be started at 30 min after anesthesia induction and before CPB application for surgery. In both groups, moderate hypothermic CPB will be initiated by using 1600-1800 ml of bloodless priming solution. The changes of hematocrit (Hct), Na+, K+, HCO3-, Ca2+, osmolarity, s-Cr will be determined before ANH (T1), after the first ANH of 2.5 ml/kg (T2), and after the second ANH of 2.5 ml/kg (T3), 30 sec and 60 sec after the initiation of CPB (T4, T5), immediately and 1 hour after the weaning from CPB (T6, T7) and at the end of surgery (T8). S-Cr will be determined by using a point-of-care test device (StatSensor™ Creatinine, Nova Biomedical, USA).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2011

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2011

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 10, 2016

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 13, 2016

Completed
Last Updated

July 13, 2016

Status Verified

July 1, 2016

Enrollment Period

4.5 years

First QC Date

July 10, 2016

Last Update Submit

July 10, 2016

Conditions

Keywords

cardiac surgeryacute normovolemic hemodilution

Outcome Measures

Primary Outcomes (1)

  • serum creatinine (s-Cr) concentration

    before ANH

Study Arms (2)

Control Group

Patients undergoing cardiac surgery supposed not to get acute normovolemic hemodilution (ANH) before CPB

Active Comparator: Acute normovolemic hemodilution group

Patients undergoing cardiac surgery supposed to get aucte normovolemic hemodilution (ANH) before CPB

Procedure: Acute normovolemic hemodilution (ANH)Drug: hydroxyethyl starch (HES 130/0.6)

Interventions

Active Comparator: Acute normovolemic hemodilution group
Active Comparator: Acute normovolemic hemodilution group

Eligibility Criteria

Age19 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients undergoing elective cardiac surgery due to valvular heart disease

You may qualify if:

  • patients undergoing cardiac surgery with cardiopulmonary bypass who signed written informed consent

You may not qualify if:

  • preoperative renal failure requiring reran replacement therapy
  • preoperative liver disease
  • preoperative low cardiac output (EF \< 50%)
  • Preoperative IABP application, Atrial fibrillation, Pacemaker,
  • contraindication for applying TEE
  • intraoperative withdrawal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Konkuk University Medical Center

Seoul, 143-729, South Korea

Location

MeSH Terms

Conditions

Mitral Valve InsufficiencyMitral Valve StenosisTricuspid Valve Insufficiency

Interventions

Hydroxyethyl Starch Derivatives

Condition Hierarchy (Ancestors)

Heart Valve DiseasesHeart DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

StarchDietary CarbohydratesCarbohydratesGlucansPolysaccharides

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Anesthesiology

Study Record Dates

First Submitted

July 10, 2016

First Posted

July 13, 2016

Study Start

December 1, 2011

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

July 13, 2016

Record last verified: 2016-07

Locations